Volumetric MRI markers and predictors of disease activity in early multiple sclerosis: a longitudinal cohort study - Cortechs.ai

Solutions
Our solutions

Advanced AI tools for improved disease prediction and monitoring

View all solutions

NeuroQuant®

Best-in-class brain segmentation and volumetric analysis

NeuroQuant® MS

Accurately visualize lesions and lesion volume change.

NeuroAlign CT

Automated CT alignment for fast, accurate diagnosis

NeuroQuant® Brain Tumor

Pre- and post-operative 3D volume analysis of brain tumors.

NeuroQuant® PET

Automated tracer activity quantification

OnQ™ Prostate

Optimizing prostate MRI for advanced clinical insights.

NeuroQuant® ARIA

Quantification of lesions to support ARIA surveillance
About
About

We merge state-of-the-art medical imaging with the power of clinical data and machine learning to empower physicians in making more accurate and timely diagnostic decisions.

Learn about Cortechs.ai

Team

The experts behind our industry-leading software and services

Careers

Join the team leading the way in radiology AI applications

Partnerships

The partnerships and strategic alliances behind Cortechs.ai

Events

Meet the Cortechs.ai team in a city near you
Support
Support

Technical and account information for existing Cortechs.ai customers

Find out more

Submit a ticket

Log an issue or query with our service team
Resources
Resources

Discover the latest AI image quantification news in your role or specialism.

Find out more

Case studies

See how Cortechs.ai solutions are elevating patient care

Video Library

View our webinars, user guides and technical specs

Industry news

What you need to know about AI radiology

Cortechs.ai news

The latest headlines from Cortechs.ai

Published research

Evidence-based validation of our impact on neuroimaging

Whitepapers

Read the whitepapers about our solutions

Volumetric MRI markers and predictors of disease activity in early multiple sclerosis: a longitudinal cohort study

November 18, 2023
< 1 mins

This study compares clinical and MRI parameters between patients with clinically isolated syndrome and those converting to clinically definite multiple sclerosis within 2 years, to identify volumetric MRI predictors of this conversion and to assess effect of early relapses. 2012.

[button]Download[/button]

Topic: Published research

Insights

02/02/2025

NeuroQuant® Brain Tumor: Revolutionizing Neuro-Oncology with AI-Driven Precision

Dr. Suzie Bash and Dr. Jeff Rudie dive deep into the advanced functionalities and clinical benefits of the tool that is revolutionizing neuro-oncology

Industry news

01/28/2025

Revolutionizing Imaging Diagnostics with Cortechs.ai CEO, Kyle Frye

Hear from CEO Kyle Frye on the SCALE Community Podcast about how Cortechs.ai is transforming healthcare with cutting-edge AI-powered medical imaging solutions.

Cortechs.ai news, Industry news

01/09/2025

Cortechs.ai Announces Oversubscribed Funding Round to Accelerate Innovation in AI-Powered Neuroimaging and Oncology Solutions

This investment propels our mission to revolutionize medical imaging in neuroimaging and oncology, enhancing diagnostic confidence and patient outcomes.

Cortechs.ai news, Industry news

Empowering precision

and clarity in patient care

5060 Shoreham Place,
Ste 240, San Diego, CA 92122